February 12, 2024 -
Precision medicine–delivering the right drug at the right time to the right patient–is the direction in which lung cancer treatment is heading. In this episode, we talk about an exciting, emerging drug class with one of the most prominent investigators involved with its development, Dr. Jonathan Spicer at McGill University’s Thoracic Oncology Network. It provides a deep dive into neoadjuvant therapy for patients who have operable lung cancer, offering insight into what is currently known about response and failure rates.
Brought to you by the American Lung Association and HCPLive
Tune in and subscribe on:
Have an idea for a future Lungcast episode? Share your idea with us!
